David C W Lau
Overview
Explore the profile of David C W Lau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
3087
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lau D, Patton I, Lavji R, Belloum A, Ng G, Modi R
Clin Obes
. 2024 Sep;
15(1):e12701.
PMID: 39228093
This mixed-methods study aimed to explore factors contributing to therapeutic inertia among people living with obesity in Canada from the perspective of general/family practitioners (GP/FPs). One-on-one interviews and online surveys...
2.
McGowan B, Bruun J, Capehorn M, Pedersen S, Pietilainen K, Muniraju H, et al.
Lancet Diabetes Endocrinol
. 2024 Aug;
12(9):631-642.
PMID: 39089293
Background: There are currently limited data regarding the effect of semaglutide 2·4 mg in individuals with obesity and prediabetes in clinical trials. We aimed to assess the efficacy and safety...
3.
Lau D, Shaw E, McMullen S, Cowling T, Witges K, Amitay E, et al.
BMC Nephrol
. 2024 Jul;
25(1):244.
PMID: 39080608
Background: Chronic kidney disease (CKD) poses a substantial burden to individuals, caregivers, and healthcare systems. CKD is associated with higher risk for adverse events, including renal failure, cardiovascular disease, and...
4.
Olivieri A, Muratov S, Larsen S, Luckevich M, Chan K, Lamotte M, et al.
Int J Obes (Lond)
. 2024 Jan;
48(5):683-693.
PMID: 38291203
Objectives: This study aimed to assess the cost-effectiveness of weight-management pharmacotherapies approved by Canada Health, i.e., orlistat, naltrexone 32 mg/bupropion 360 mg (NB-32), liraglutide 3.0 mg and semaglutide 2.4 mg...
5.
Lau D, Patton I, Lavji R, Belloum A, Ng G, Modi R
Diabetes Obes Metab
. 2024 Jan;
26(4):1529-1539.
PMID: 38284284
Aims: To identify and better understand themes related to why people living with obesity (PwO) in Canada may not use professional support and to explore potential strategies to address the...
6.
Lau D, Shaw E, Farris M, McMullen S, Brar S, Cowling T, et al.
Can J Diabetes
. 2023 Dec;
48(3):155-162.e8.
PMID: 38135113
Objectives: Type 2 diabetes mellitus (T2DM) is a prevalent chronic disease and a leading cause of morbidity/mortality in Canada. We evaluated the burden of T2DM in Alberta, Canada, by estimating...
7.
Jain R, Stone J, Agarwal G, Andrade J, Bacon S, Bajaj H, et al.
CMAJ
. 2023 Jan;
195(1):E21-E42.
PMID: 36623864
No abstract available.
8.
Jain R, Stone J, Agarwal G, Andrade J, Bacon S, Bajaj H, et al.
CMAJ
. 2022 Nov;
194(43):E1460-E1480.
PMID: 36343954
No abstract available.
9.
Lau D, Batterham R, le Roux C
Expert Rev Clin Pharmacol
. 2022 Apr;
15(3):251-267.
PMID: 35466848
Introduction: The recent approval in the USA (Food and Drug Administration), Canada (Health Canada), UK (Medicines and Healthcare products Regulatory Agency), and EU (European Medicines Agency) of once-weekly injectable semaglutide...
10.
Lau D, Erichsen L, Francisco A, Satylganova A, le Roux C, McGowan B, et al.
Lancet
. 2021 Nov;
398(10317):2160-2172.
PMID: 34798060
Background: Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide is a long-acting amylin analogue under investigation for weight management. We assessed the dose-response relationship of cagrilintide regarding the...